GLP1R and metabolic dysfunction-associated steatohepatitis: The aim of this study was to systematically review randomized controlled trials assessing the efficacy and safety of resmetirom, GLP-1 receptor agonists, and dual GIP/GLP-1 receptor agonists in adults with biopsy-confirmed, non-cirrhotic MASH (F2-F3), and to evaluate the certainty of evidence using Grading of Recommendations Assessment, Development and Evaluation (GRADE).